![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Antiviral activity, exposure-response, and resistance analyses of monotherapy with the novel HIV nucleoside reverse transcriptase inhibitor
(NRTI) BMS-986001 in antiretroviral treatment-experienced subjects
|
|
|
Reported by Jules Levin
13th International Workshop on Clinical Pharmacology of HIV Therapy
16-18 April 2012, Barcelona, Spain
C Hwang,1 L Zhu,1 HM Chan,1 I Chang,1 GJ Hanna,1 R Bertz,1 D Grasela1
1Bristol-Myers Squibb, Research and Development, Princeton, NJ, USA
![PK1.gif](../images/041712/041712-3/PK1.gif)
![PK2.gif](../images/041712/041712-3/PK2.gif)
![PK3.gif](../images/041712/041712-3/PK3.gif)
![PK4.gif](../images/041712/041712-3/PK4.gif)
![PK5.gif](../images/041712/041712-3/PK5.gif)
![PK6.gif](../images/041712/041712-3/PK6.gif)
![PK7.gif](../images/041712/041712-3/PK7.gif)
![PK8.gif](../images/041712/041712-3/PK8.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|